JP Morgan Reinstates Underweight on Emergent BioSolutions
Portfolio Pulse from Benzinga Newsdesk
JP Morgan analyst Jessica Fye has reinstated Emergent BioSolutions (NYSE:EBS) with an Underweight rating.
November 20, 2023 | 1:28 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
JP Morgan analyst Jessica Fye reinstated coverage on Emergent BioSolutions with an Underweight rating, which could negatively impact the stock's performance in the short term.
Analyst ratings can significantly influence investor sentiment and stock prices. An Underweight rating suggests that the analyst believes the stock will underperform its sector or the overall market, which can lead to a decrease in its share price. Given that this rating comes from a major financial institution like JP Morgan, it is likely to be taken seriously by the market.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100